LL-37

What it is

LL-37 is a 37-amino-acid antimicrobial peptide derived from the C-terminal end of human cathelicidin antimicrobial protein-18 (hCAP-18). The “LL” in the name refers to the two leucine residues at the N-terminus of the active fragment. LL-37 is the only cathelicidin in humans (other species have multiple cathelicidins), making it a critical component of human innate immunity.

LL-37 is produced by neutrophils, mast cells, NK cells, B-cells, and epithelial cells throughout the body — particularly at barrier surfaces (skin, gut, respiratory tract, urinary tract) where pathogen exposure is highest. Vitamin D is a key transcriptional regulator of LL-37 production, which is one of the mechanisms underlying vitamin D’s connections to immune competence and infection susceptibility.

Synthetic LL-37 has been in research use for decades and is increasingly available through licensed compounding pharmacies for clinical applications. It is not FDA-approved for any indication. The peptide and its analogs are an active area of antimicrobial drug development, particularly given the global concern about antibiotic resistance.

Mechanism of action

LL-37 acts through both direct antimicrobial activity and immunomodulatory effects:

• Direct membrane disruption: the peptide’s amphipathic α-helical structure allows insertion into bacterial membranes, where it disrupts membrane integrity and causes bacterial lysis. This mechanism is broadly active against gram-positive and gram-negative bacteria, fungi, and enveloped viruses.
• Biofilm activity: LL-37 has documented activity against biofilm-forming organisms, which is clinically significant because biofilms are inherently resistant to most conventional antibiotics. This is one of LL-37’s most clinically relevant features.
• Anti-resistant organism activity: active against MRSA, VRE, and certain multidrug-resistant gram-negatives that are difficult to treat with conventional antibiotics.
• Immunomodulation: LL-37 modulates inflammatory responses, supports wound healing, and influences adaptive immune cell function. The net effect varies with concentration and context but generally promotes effective immune response without excessive inflammation.
• Anti-endotoxin activity: LL-37 binds and neutralizes lipopolysaccharide (LPS) from gram-negative bacteria, reducing the inflammatory response to bacterial cell wall fragments.
• Wound healing: promotes re-epithelialization and tissue repair, which is integrated with its antimicrobial role at barrier surfaces.

Research findings

The preclinical literature on LL-37 is extensive, supporting the broad antimicrobial and immunomodulatory profile described above. Endogenous LL-37 deficiency is associated with chronic infection susceptibility and certain inflammatory skin conditions.

Chronic infection and biofilm states: studies have explored LL-37 in chronic wound infections, chronic rhinosinusitis with biofilm, and other persistent infection scenarios. Results suggest meaningful activity against organisms that resist conventional therapy.

Inflammatory skin conditions: LL-37 has roles in psoriasis (where overproduction may contribute) and atopic dermatitis (where deficiency may contribute). Therapeutic applications target these patterns of dysregulation.

Sepsis and severe infection: small clinical and preclinical studies have explored LL-37 in severe infection scenarios, with the rationale being both direct antimicrobial activity and LPS neutralization.

Wound healing: topical formulations have been studied for chronic wounds with promising results.

Large RCT data validating specific clinical indications is limited. Most clinical use is informed by mechanism, preclinical evidence, and accumulating practitioner experience.

How we use it at The Tide

LL-37 is among our more selectively used peptides. We prescribe primarily for:

• Chronic biofilm-associated infections: chronic sinusitis with documented biofilm, chronic prostatitis, recurrent urinary tract infections with imaging or symptom features suggesting biofilm involvement
• Recurrent gut infections: often combined with KPV and BPC-157 in protocols addressing both the antimicrobial and inflammatory components
• Chronic Lyme and related tick-borne infection syndromes: in coordination with the patient’s primary infectious disease care
• Selected inflammatory skin conditions where antimicrobial component is present
• Adjunct therapy in patients with documented frequent infections who have completed appropriate immunological workup

Standard dosing: 100–200 mcg subcutaneously daily for 4–6 week cycles. We typically do not extend single cycles beyond 6 weeks given limited long-term safety data and the immune-modulating nature of the peptide.

What good response looks like: patients with chronic infection presentations typically report symptom improvement within 2–3 weeks, with continued progress through the cycle. Patients who see no benefit by week 3 are unlikely to benefit from extension.

Side effects and contraindications

LL-37 is generally well-tolerated:

• Mild injection site reactions are most common
• Some patients report transient fatigue or flu-like symptoms in the first few doses, consistent with immune activation. Usually resolves within a week.
• Rare nausea or GI upset with first doses

Caution areas:

• Active autoimmune conditions: the immune-modulating effects warrant careful evaluation in patients with autoimmune diagnoses. We coordinate with the patient’s rheumatology team when relevant.
• Patients on immunosuppression: theoretical interaction; we evaluate case-by-case.
• Pregnancy and breastfeeding: avoided in absence of safety data.
• Sepsis or severe acute infection: not used in the outpatient setting; severe acute infection requires hospital-level care.

What we don’t yet know

Optimal dosing for various clinical scenarios is largely empirical. Long-term safety beyond 6-week cycles is not well characterized. The relative effectiveness of LL-37 vs. conventional antibiotic approaches for specific infections is not well documented in head-to-head studies. The role of LL-37 in modulating the broader microbiome (vs. acting only on pathogenic organisms) is an area of active research with implications for prolonged use. Optimal patient selection criteria for various indications would benefit from formal trial data that is not currently available. We present LL-37 honestly as an emerging tool with strong mechanistic basis and growing clinical experience, used selectively for specific indications rather than as a general antimicrobial.